Global Myelodysplastic Syndrome (MDS) Treatment Market, By Drug (Azacitidine, Lenalidomide, Decitabine, Deferasirox), and Geography - Insights, Size, Share, Opportunity Analysis, & Industry Forecast till 2025
- Report code : CMI6775 |
- Industry :
Pharmaceutical
- Published On : Sep 2017 |
- Pages : 95 Pages |
- Format :
Myelodysplastic Syndrome Treatment Market
Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more often in older men than women. This syndrome is characterized by certain chromosomal mutations in Janus Kinase gene which include deletion of q arm in one or more chromosomes and complete deletion of chromosome 5 or 7 and an extra copy of chromosome 8. There are various types of myelodysplastic syndrome such as refractory cytopenia with unilineage dysplasia and refractory anemia with ringed sideroblasts among others. Approved drugs for MDS include Vidaza (Azacitidine), Revlimid (Lenalidomide), Decitabine (Dacogen), and Deferasirox (Jadenu). Revlimid (Lenalidomide) patent for MDS indication will be expiring in 2023. A number of generic azacitidine-based products for MDS are launched in the global market.
Rising implications associated with myelodysplastic syndrome are expected to affect the myelodysplastic syndrome treatment market
According to the American Cancer Society, the incidence rate for myelodysplastic syndrome is 13,000 new cases each year which happens at a rate of 4.8 cases per 100,000 people. This trend is heavily affected or rather influenced by the average age of the population which, according to the World Health Organization (WHO), is increasing and is expected to double from 12% to 22% between 2015 and 2050. Furthermore, according to the American Society of Clinical Oncology (ASCO), age plays an important role in the occurrence of myelodysplastic syndrome as most of the people diagnosed with the disease are of age 65 and older. These factors are expected to boost the myelodysplastic syndrome treatment.
The global myelodysplastic syndrome treatment market was valued at US$ 2,213.2 million in 2017 and is expected to witness a CAGR of 12.7% during the forecast period (2017 – 2025).
Table 1. Myelodysplastic Syndrome Drugs Pipeline
|
Drug/ Candidate |
Phases |
|
Revlimid |
Phase 3 (Deletion 5q) |
|
Durvalumab (PD-L1 Inhibitor) |
Phase 2 |
|
Luspatercept |
Phase 2 (Low risk MDS) |
|
Azacitidine |
Phase 3 ( Low risk MDS) |
|
CC-90002 (Anti-CD47 Inhibitor) |
Phase 1 (Post HMA failure) |
Source: Coherent Market Insights Analysis (2017)
Endeavor to introduce highly effective therapies for various MDS types would support the market growth
Major pharmaceutical organizations such as Celgene are investing major amounts in research and development of MDS specific drugs and many of their drugs are showing potential in the clinical trials as shown in the table no.1. Furthermore, in 2016, Opsona Therapeutics Ltd. received orphan drug designation for its OPN-305 humanized IgG4 monoclonal antibody for MDS treatment. Also, after Celgene lost its U.S. exclusivity for Vidaza, many generic formulations have entered in the market for Vidaza and Natco Pharma is also expected to launch generic version of Vidaza in 2017, which will further boost myelodysplastic syndrome treatment market.
Increasing knowledge about the disease and its symptoms with advanced methods and techniques for early diagnosis and treatment for various forms of the disease is fuelling the market growth. The American Cancer Society estimates that, about 1/3rd of the MDS patients can rapidly advance to cancer of bone marrow cells called as acute myeloid leukemia. Thus, increased understanding of the pathology of the syndrome is directing the research towards developing more specialized and symptom based treatments with effective costs, so that majority of the MDS patients can avail these benefits.
- The genetic transformations associated with the disease and biologics of the MDS is being explored. Diagnosis and treatment options are being researched at various standard cancer research centers. Mutations of TP53, TET2, and DNMT3A have been identified as possible MDS patients with shorter OS after allogenic HSCT which suggests the need of alternative treatment options than transplantation.
- Extensive research studies are being performed on existing treatment options such as chemotherapy, immune suppression, targeted therapy, stem cell transplant, and drugs to raise platelet counts such as Romiplostim (Nplate), which is used as a therapy for a disease called as Immune thrombocytopenic purpura (ITP). However, recent studies reports to have increased platelet counts in people with MDS according to the American Cancer Society.
Awareness initiatives to lead to early diagnosis and treatment
Furthermore, governmental organizations and drug manufacturing companies are spreading awareness about the disease with various ways, such as by providing funding and conducting awareness programs. MDS International Foundation is one such organization which is supporting the patients through various ways be it treatment or psychological support. Furthermore EvansMDS a funding initiative of the Edward P.Evans Foundation has awarded $45 Mn since 2011 for research specifically focused on MDS and AML.
Key players operating in the myelodysplastic syndrome treatment market include Celgene, Novartis, and Otsuka. Some of the other market players are Astellas, Astex, Acceleron Pharma, Onconova Pharmaceuticals, GlaxoSmithKline, Eli-Lilly, and CTI Biopharma.
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around 30% of the patients, known as Acute Myeloid Leukemia (AML). MDS is most commonly found in aging population and remains an incurable disease in majority of patients. According to the American Cancer Society, over 13,000 new cases of MDS occur in the U.S. every year. This is expected to drive the growth of myelodysplastic syndrome treatment market. Hypomethylating drugs such as azacitidine and decitabine help stimulate blood cells to mature and improve blood cell production in MDS.
Market Dynamics
According to the American Society of Hematology, in 2016, prevalence of MDS ranged from 0.22-13.2 per 100,000, on all age categories and ethnicities globally. Increasing public awareness about the disease and introduction of new treatment for MDS will drive the growth of the market. Furthermore, growing aging population is analyzed to be a major factor propelling the growth of myelodysplastic syndrome treatment market. According to NCBI, 2012, the incidence of MDS increases significantly with age and the disease is most prevalent in males. Besides, companies such as Celgene and Novartis, who offer innovative brands in this market would be able to combat the loss of share, post patent expiry through their pipeline molecules expected to be launched during the forecast period.
Market Taxonomy
This report segments the global myelodysplastic syndrome treatment market on the basis of drugs. On the basis of drugs, the global Myelodysplastic syndrome treatment market is classified into Azacitidine, Lenalidomide, Decitabine, and Deferasirox. For comprehensive understanding of market dynamics, the global myelodysplastic syndrome treatment market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the market.
Key features of the study:
- This report provides in-depth analysis of myelodysplastic syndrome treatment and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2016 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global myelodysplastic syndrome treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
- Key companies covered as a part of this study include Novartis AG, Celgene Corporation, Otsuka Pharmaceutical Co., Ltd., Sandoz Inc., Dr Reddys Laboratories Limited, Pharmascience Inc., Accord Healthcare Ltd, Mylan N.V.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion and marketing tactics
- The global myelodysplastic syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, Myelodysplastic syndrome treatment manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the myelodysplastic syndrome treatment market
Detailed Segmentation:
- Global Myelodysplastic syndrome treatment market, By Drug:
- Azacitidine
- Lenalidomide
- Decitabine
- Deferasirox
- Global Myelodysplastic syndrome treatment market, By Geography:
- North America
- By Country
- U.S.
- Canada
- By Drug
- Azacitidine
- Lenalidomide
- Decitabine
- Deferasirox
- By Country
- Europe
- By Country
- Germany
- Italy
- France
- Russia
- Rest of the Europe
- By Drug
- Azacitidine
- Lenalidomide
- Decitabine
- Deferasirox
- By Country
- North America
- Asia Pacific
- By Country
- China
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- By Drug
- Azacitidine
- Lenalidomide
- Decitabine
- Deferasirox
- Latin America
- By Country
- Mexico
- Rest of Latin America
- By Drug
- Azacitidine
- Lenalidomide
- Decitabine
- Deferasirox
- Middle East
- By Country
- GCC
- Israel
- By Drug
- Azacitidine
- Lenalidomide
- Decitabine
- Deferasirox
- By Country
- Africa
- By Country
- North Africa
- Central Africa
- South Africa
- By Drug
- Azacitidine
- Lenalidomide
- Decitabine
- Deferasirox
- By Country
- Company Profiles
- Novartis AG*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Future Plans
- Celgene Corporation
- Otsuka Pharmaceutical Co., Ltd.
- Sandoz Inc.
- Dr Reddys Laboratories Limited
- Pharmascience Inc
- Accord Healthcare Ltd
- Mylan N.V.
- Novartis AG*
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
- Research Objective and assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet By Drug
- Market Snippet By Region
- Coherent Opportunity Map (COM)
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Supply Side Drivers
- Demand Side Drivers
- Economic Drivers
- Restraints
- Market Opportunities
- Regulatory Scenario
- Epidemiology/Prevalence/Incidence
- Product Pipeline
- Global Myelodysplastic syndrome Treatment Market, By Drug, 2015 – 2025 (USD Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-O-Y Growth Analysis, 2017 - 2025
- Segment Trends
- Azacitidine
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2025, (USD Million)
- Lenalidomide
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2025, (USD Million)
- Decitabine
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2025, (USD Million)
- Deferasirox
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2025, (USD Million)
- Global Myelodysplastic syndrome Treatment Market, By Regions, 2015 – 2025 (USD Million)
- Introduction
- Market Share Analysis, By Region, 2016 and 2025 (%)
- Y-O-Y Growth Analysis, For Regions, 2017 - 2025
- North America
- Market Share Analysis, By Country, 2017 and 2025 (%)
- Y-O-Y Growth Analysis, By Country, 2017 - 2025
- U.S.
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Canada
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Market Share Analysis, By Drug, 2016 and 2025 (%)
- Y-O-Y Growth Analysis, By Drug, 2017 – 2025
- Azacitidine
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Lenalidomide
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Decitabine
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Deferasirox
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Europe
- Market Share Analysis, By Country, 2016 and 2025 (%)
- Y-O-Y Growth Analysis, By Country, 2017 - 2025
- U.K.
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Germany
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Italy
- Market Size and Forecast, 2015 - 2025 (USD Million)
- France
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Russia
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Rest of the Europe
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Market Share Analysis, By Drug, 2016 and 2025 (%)
- Y-O-Y Growth Analysis, By Drug, 2017 – 2025
- Azacitidine
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Lenalidomide
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Decitabine
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Deferasirox
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Asia Pacific
- Market Share Analysis, By Country, 2016 and 2025 (%)
- Y-O-Y Growth Analysis, By Country, 2017 - 2025
- China
- Market Size and Forecast, 2015 - 2025 (USD Million)
- India
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Japan
- Market Size and Forecast, 2015 - 2025 (USD Million)
- ASEAN
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Australia
- Market Size and Forecast, 2015 - 2025 (USD Million)
- South Korea
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Rest of Asia Pacific
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Market Share Analysis, By Drug, 2016 and 2025 (%)
- Y-O-Y Growth Analysis, By Drug, 2017 - 2025
- Azacitidine
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Lenalidomide
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Decitabine
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Deferasirox
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Latin America
- Market Share Analysis, By Country, 2016 and 2025 (%)
- Y-O-Y Growth Analysis, By Country, 2017 - 2025
- Brazil
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Mexico
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Rest of Latin America
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Market Share Analysis, By Drug, 2016 and 2025 (%)
- Y-O-Y Growth Analysis, By Drug, 2017 - 2025
- Azacitidine
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Lenalidomide
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Decitabine
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Deferasirox
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Africa
- Market Share Analysis, By Country, 2016 and 2025 (%)
- Y-O-Y Growth Analysis, By Country, 2017 - 2025
- Northern Africa
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Central Africa
- Market Size and Forecast, 2015 - 2025 (USD Million)
- South Africa
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Market Share Analysis, By Drug, 2016 and 2025 (%)
- Y-O-Y Growth Analysis, By Drug, 2017 - 2025
- Azacitidine
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Lenalidomide
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Decitabine
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Deferasirox
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Middle East
- Market Share Analysis, By Country, 2016 and 2025 (%)
- Y-O-Y Growth Analysis, By Country, 2017 - 2025
- GCC Countries
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Israel
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Market Share Analysis, By Drug, 2016 and 2025 (%)
- Y-O-Y Growth Analysis, By Drug, 2017 - 2025
- Azacitidine
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Lenalidomide
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Decitabine
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Deferasirox
- Market Size and Forecast, 2015 - 2025 (USD Million)
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis (3x3 Matrix)
- Company Profiles
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Celgene Corporation
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Otsuka Pharmaceutical Co., Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Sandoz Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Dr Reddys Laboratories Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Pharmascience Inc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Accord Healthcare Ltd
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Mylan N.V.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
*Browse 45 market data tables and 23 figures on "Myelodysplastic Syndrome Treatment Market - Global forecast to 2025”.
Share
Choose License Type
"How Can I Help You" ?
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Key Benefits
Custom Research Solution
Talk to our research consultant to design an exclusive report as per your research needs.
Customer Fulfilment
We aim to fulfil client's research demands with tailored research solutions.
Quick Turnaround Time Reports
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
360-degree Approach
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
Assured Quality
We strive to provide most accurate and reliable research findings in our research reports.